Navigation Links
Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
Date:1/15/2008

REINACH, Switzerland, January 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it has received authorisation from the U.S. Food and Drug Administration (FDA) to conduct a Phase II 'intravenous-to-oral' switch trial with iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with intravenous (IV) vancomycin in the treatment of cSSSI. The primary endpoint will be the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcomes as well as safety and tolerability.

This Phase II trial is designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI will receive IV vancomycin for the first two days of treatment and will then be randomised to either continue to receive IV vancomycin or be switched to oral iclaprim for eight additional days. A total of 60 patients will be randomised for this study.

Iclaprim is also being developed as an intravenous formulation for two indications: cSSSI and nosocomial pneumonia. In the cSSSI indication the drug candidate has completed its pivotal Phase III trial programme and is currently in an NDA-filing process. In the nosocomial pneumonia indication, the drug candidate is currently in Phase II.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "Among the hospital anti-MRSA drugs that are currently in filing or late-stage development, only iclaprim shows good oral bioavailability and consequently offers the potential for intravenous-to- oral switch therapy. We believe that intravenous-to-oral switch therapy is important as it could provide a means to enhance patient comfort, reduce risk of spread of infection and reduce hospital-associated healthcare costs. In parallel with this Phase II trial, we are continuing our work on th
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida-Supported CME Symposium Available Online
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Arpida Presents Preclinical Data on AR-2474 at ICAAC
4. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
5. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
6. Arpida Interim Results for six Months to 30 June 2007
7. Genta Receives Notice of Non-Compliance With NASDAQ Rule
8. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
9. Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
10. EaglePicher Technologies Receives Battery Power Products and Technologys First Annual Innova Award
11. Aida Receives Chinese Government Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Incorporated (SPEX) -- an intellectual property development company committed to ... the United States Patent & Trademark Office (USPTO) issued a ... that is part of a standard essential family of patents. ... , Application number: US 13/728,867 , Publication date: Sep ... The listed inventors of the new patent, entitled ...
(Date:9/21/2014)... discovered how to produce ultra-thin "diamond nanothreads" that promise ... of today,s strongest nanotubes and polymers. A paper describing ... V. Badding, a professor of chemistry at Penn State ... issue of the journal Nature Materials . , ... intriguing because the threads we formed have a structure ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
(Date:9/20/2014)... Friesland, Netherlands (PRWEB) September 20, 2014 ... cell technologies to perform a groundbreaking surgery at the ... incident, the mare's superficial digital flexor tendon was ruptured ... this kind of injury is a death sentence for ... MediVet America stem cell treatments . This ...
Breaking Biology Technology:Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... 4 ARCA Discovery Inc., a privately held,biopharmaceutical ... other cardiovascular diseases, today announced Richard B.,Brewer, President ... 26th,Annual JPMorgan Healthcare Conference on Tuesday, January 8 ... Conference will be held January 7-10, 2008 at,the ...
... REYKJAVIK, Iceland, Jan. 4 deCODE genetics,(Nasdaq: DCGN ... webcast of deCODE,CEO Kari Stefansson,s presentation at the JPMorgan ... at 11:30 am PST / 7:30 pm GMT on,Thursday, ... California.,The webcast can be accessed through the Investors page ...
... FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, Inc. announced ... Counsel, a newly established position, and Vice President ... global life sciences,executive and corporate attorney with broad ... in the US and,Europe. In the business development ...
Cached Biology Technology:ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008 2Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2
(Date:9/21/2014)... 2014The story of cowpea (black-eyed peas) is a fascinating ... problemseven more fascinating is the story of the scientist ... The Food Legume of the 21st Century to serve ... use. The book was recently published by the Crop ... of Tropical Agriculture (IITA). , Singh has devoted his ...
(Date:9/21/2014)... recent years, new strains of bacteria have emerged that ... superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect ... least 23,000. Despite the urgent need for new treatments, ... in the past decade. , MIT engineers have now ... a gene-editing system that can disable any target gene, ...
(Date:9/21/2014)... team of Stanford researchers has developed a protein therapy ... break away from original tumor sites, travel through the ... the body. , This process, known as metastasis, can ... "The majority of patients who succumb to cancer fall ... Cochran, an associate professor of bioengineering who describes a ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... Md. -- Later this week, the American Society of Plant ... plant science to chart the future of the field. The ... the broad plant science research community in a process that ... science research over the next decade. The summit will ...
... A University of Alberta research team has turned their ... and hopes to expand its use. U ... students produced a 3-D imaging system called Virtual Reflected-Light ... a light source, a platform that moves the objects ...
... woodland creatures, including woodlice, millipedes and worms, can help ... according to new research from Cardiff University. Huge ... compete with each other for space and resources and, ... woodland floor have the potential to govern the outcome ...
Cached Biology News:ASPB convenes leaders to chart future of plant science research 2Peacekeeping creatures help maintain woodland diversity 2
... dispenser combining the most versatile features for bulk ... existing Multidrop dispensers. , ,It is designed ... nl up to 2500 l with excellent precision ... for multiple plate formats (96, 384, 1536) including ...
... Multidrop Combi is a new generation bulk ... flexibility and simplicity for pharmaceutical and biotech ... reliable Multidrop range, Multidrop Combi has been ... volumes of 0.5-2500 l and multiple plate ...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Biology Products: